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Congenital heart block develops in fetuses after placental transfer of Ro/SSA autoantibodies 
from rheumatic mothers. The condition is often fatal and the majority of live-born children 
require a pacemaker at an early age. The specific antibody that induces the heart block and 
the mechanism by which it mediates the pathogenic effect have not been elucidated. In this 
study, we define the cellular mechanism leading to the disease and show that maternal 
autoantibodies directed to a specific epitope within the leucine zipper amino acid sequence 
200–239 (p200) of the Ro52 protein correlate with prolongation of fetal atrioventricular 
(AV) time and heart block. This finding was further confirmed experimentally in that pups 
born to rats immunized with p200 peptide developed AV block. p200-specific autoantibodies 
cloned from patients bound cultured cardiomyocytes and severely affected Ca
 
2
 
  
 
oscillations, 
leading to accumulating levels and overload of intracellular Ca
 
2
 
  
 
levels with subsequent loss 
of contractility and ultimately apoptosis. These findings suggest that passive transfer of 
maternal p200 autoantibodies causes congenital heart block by dysregulating Ca
 
2
 
  
 
homeostasis 
and inducing death in affected cells.
 
Many autoimmune conditions are associated
with increased risk of pregnancy complications
and fetal loss. Complete congenital atrioven-
tricular (AV) heart block develops in the fetus
in 2–5% of Ro/SSA autoantibody-positive
pregnancies of rheumatic women, usually be-
tween 18 and 24 wk of gestation (1, 2). Initi-
ated as a first-degree AV block (3), the condi-
tion progresses to a complete third-degree AV
block after mononuclear cell infiltration, fibro-
sis, and calcification of the cardiac tissue (4, 5).
The Ro/SSA antigen is intracellular and
contains Ro52 and Ro60 protein components
to which autoantibodies are induced in the
mother (6). Systematic analyses have been un-
dertaken to identify the subpopulation and
specificity of Ro/SSA antibodies that correlate
with congenital heart block (7–9). Recent
studies indicate that antibodies recognizing the
Ro52 protein of the Ro/SSA complex are
pathogenic (3, 9), and more specifically, our
studies have demonstrated that antibodies to
amino acids 200–239 (p200) of the Ro52 pro-
tein were detected in the mothers of children
with complete heart block (9). However, the
fine specificity and the mechanism by which
p200-specific antibodies mediate heart block
have not been elucidated.
We and others have shown that early treat-
ment of an incomplete block with high dose
fluorinated steroids prevents progression of, or
even reverts, the block, decreasing fetal mor-
bidity and mortality (3, 10, 11). However, a
complete third-degree block is permanent
(11), making it relevant also from a clinical
point of view to define the specific antibody-
mediating heart block. A marker with high
predictability could identify high risk pregnan-
cies and allow initiation of treatment at the
critical stage to prevent irreversible heart block
in the fetus.
In this paper, we show that not all, but
Ro52 autoantibodies with a particular specific-
ity for the p200 sequence of the Ro52 protein
correlate with AV time prolongation in the fe-
tus, bind the surface of cardiomyocytes, and
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induce Ca
 
2
 
  
 
dysregulation and ultimately apoptosis in af-
fected cells.
 
RESULTS AND DISCUSSION
Maternal anti-p200 antibody levels correlate with neonatal 
AV conduction time
 
To evaluate the role of Ro52 antibodies in development of
congenital heart block, we followed 25 pregnant Ro52 au-
toantibody-positive women prospectively with weekly fetal
echocardiographic examinations between 18 and 24 wk of
gestation. Maternal autoantibodies to different parts of the
Ro52 protein (Fig. 1 A) were investigated by ELISA. Fetal
AV time was defined using two different Doppler techniques
(Fig. 1, B and C), and development of heart block was cor-
related with antibody specificity. 9 of the 25 (36%) fetuses
had signs of first-degree AV block by both methods. One of
these nine developed a second-degree and another a com-
plete AV block (Videos 1 and 2, available at http://www.
jem.org/cgi/content/full/jem.20041859/DC1). We found
a significant correlation between prolongation of AV time
and levels of antibodies to amino acids 200–239 (p200) of
Ro52 (P 
 
  
 
0.02). Mothers of fetuses developing second-
and third-degree AV block were found among those with
the highest levels of p200 antibodies (Fig. 1, D and E). In
mothers of less affected fetuses, the Ro52 antibody response
was mainly directed to the p176 peptide (amino acids 176–
196) of the Ro52 protein, and interestingly, the ratio of
p200/p176 antibody levels correlated more significantly with
AV time prolongation (P 
 
  
 
0.005; Fig. 1, F and G).
 
p200 immunization of rats leads to AV block in the pups
 
To directly test whether antibodies to the p200 amino acid
stretch of Ro52 were responsible for development of heart
block, we immunized female DA rats with p200 or a control
peptide. A specific antibody response to p200 peptide and
full-length Ro52 protein developed in p200-immunized an-
imals, but not in control immunized animals (Fig. 2, A and
B). The antibodies also bound the overlapping peptide p197,
but there was no response to any of the other Ro52 pep-
tides, suggesting that no epitope spreading to adjacent pep-
tides occurred (Fig. 2 C). The antibodies to p200 were
mainly of IgG2a, IgG2b, and IgG2c subclasses (Fig. 2 D).
The animals were boosted several times, and when stable
anti-p200 titers were observed, rats were mated and the ef-
fects on the cardiac conduction system in the offspring were
evaluated by electrocardiogram (ECG) within 12 h after
birth (Fig. 2, E and F). About 20% (10/52) of the pups ex-
posed to anti-p200 antibodies during their fetal life devel-
oped a first-degree AV block (Fig. 2 G), whereas none of the
pups from control immunized mothers had heart block.
 
A similar epitope is recognized by antibodies from children 
with congenital heart block, rat pups with AV block, and a 
human p200 monoclonal
 
To generate a monospecific source of human p200 antibodies,
we screened phage display libraries derived from peripheral B
cells of Ro52 antibody-positive patients (12). Two clones, de-
noted S3A8 and M4H1, with binding specificity for Ro52 and
p200 were isolated by this technology. A set of mutated p200
peptides was designed to determine the fine epitope specificity
of the two human monoclonal antibodies and to explore possi-
ble structural as well as linear epitopes within the 
 
 
 
-helical p200
fold (Fig. 3 A). The peptide pZIP was designed to create an op-
timal leucine zipper with high dimer stability (Fig. 3 B), thus
inhibiting binding to the dimer interface. In pOUT, negatively
charged amino acids on the outer surface of the predicted zip-
per were substituted for positively or uncharged residues to alter
the antigenicity while maintaining an intact structure. The dif-
Figure 1. Maternal anti-p200 antibody levels correlate with fetal 
AV time. (A) Schematic representation of Ro52, indicating functional 
domains with two zinc fingers, a RING finger and a B-box (gray boxes), a 
leucine zipper (black box; amino acids 211–232) within a coiled coil 
domain (white box), and a B30.2 domain (white box), as well as peptides 
p136–p200. Echocardiographic representation of fetal hearts illustrating 
the view for (B) mitral valve/aortic outflow (MAV-time) measurement and 
(C) superior vena cava/aorta (SAV-time) measurement with a Doppler 
registration from each projection. Circles mark the area from where the 
registrations are sampled. LV, left ventricle; RA, right atrium; RV, right 
ventricle; AO, ascending aorta; SVC, superior vena cava. (D–G) Maternal 
anti-p200 levels and the ratio of anti-p200/anti-p176 antibodies plotted 
against the highest AV time intervals measured in each fetus. Vertical lines 
represent the upper 95% reference limits at 24 wk of gestation. Horizontal 
lines are drawn to exemplify the potential of antibody analyses to identify 
fetuses with prolonged AV time intervals. Square and diamond dots de-
note the fetuses with AV block II and III, respectively. Clinical data of these 
patients have been previously presented (reference 3). 
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ference in antigenicity between p200 and p197 also prompted
us to generate peptides for an alanine scan of residues 233–239
to evaluate the antigenic contribution from COOH-terminal
amino acids not included in p197 (Fig. 3 B).
Both monoclonals bound p200, but not the p197 peptide
(Fig. 3, C and D). S3A8 (Fig. 3 C) showed markedly re-
duced binding to the pZIP peptide and no binding to the
pOUT peptide, whereas the M4H1 antibody (Fig. 3 D)
bound well to the pOUT peptide, but showed compara-
tively reduced binding to the pZIP peptide. The pA233 ala-
nine substitution caused loss of all binding in interaction
with M4H1 antibodies, whereas the S3A8 epitope was less
affected. Sera from newborn children with congenital heart
block and sera from immunized rats were subject to similar
analysis with mutated peptides and demonstrated a fine spec-
ificity similar to the S3A8 monoclonal antibody, although
the rat sera were more heterogeneous in their reactivity and
reacted with a larger set of peptides (Fig. 3, E and F). Simi-
larly to S3A8, sera from children with congenital heart block
did not bind to pZIP or pOUT, whereas the rat sera bound
to some extent. From these data we concluded that antibod-
ies of the S3A8 specificity are present at high levels in sera
from newborn children with congenital heart block, whereas
antibodies of the M4H1 specificity were less commonly rep-
resented and/or at low levels.
 
p200 antibodies bind the cell surface and dysregulate 
calcium homeostasis in cardiomyocytes, leading to cell death
 
Our results from both human and animal studies indicate that
antibodies to p200 are involved in the development of con-
genital heart block. However, whether p200-specific antibod-
ies can bind to cardiomyocytes and induce pathogenic effects
has not been addressed. To directly investigate this issue, we
established primary cardiomyocyte cultures from neonatal rat
hearts. First, cell surface binding was examined and S3A8, but
not the M4H1, monoclonals displayed binding (Fig. 4 A).
Ca
 
2
 
  
 
is one of the main regulators of cardiomyocyte pace-
making and contractility, and to evaluate the effect of p200
autoantibodies on cardiomyocyte function we measured Ca
 
2
 
 
 
oscillations using Fluo-4 dye under a laser confocal micro-
scope at steady-state level and after the addition of antibody.
S3A8, but not M4H1 or vehicle (PBS), had a profound
effect on oscillations and survival of the cardiomyocytes.
When S3A8 was added to spontaneously contracting and os-
cillating cardiomyocytes, we noted an initial phase of in-
creased frequency of Ca
 
2
 
  
 
transients. This was followed by a
progressive decrease in frequency of Ca
 
2
 
  
 
oscillations, result-
ing in accumulation of intracellular Ca
 
2
 
 
 
, loss of Ca
 
2
 
  
 
oscil-
lations, and contractility and subsequent cell death of the
cardiomyocytes (Fig. 4, B–F). After 1 hr, no cells exhibiting
Ca
 
2
 
  
 
oscillations or contractions were observed in S3A8-
treated cardiomyocytes (Fig. 4 D), and after 24 h, no con-
tracting cells were observed. In contrast, cells in cultures
treated with M4H1 antibody still exhibited a similar Ca
 
2
 
 
 
load and oscillating and contracting activity with unchanged
frequency at both 60 min and 24 h of treatment (Fig. 4, D–F).
Cellular Ca
 
2
 
  
 
overload triggers apoptosis (13), and cell death
via this pathway in S3A8-treated cells was confirmed by
caspase-3 and TUNEL staining (not depicted). Quiescent
cells not displaying spontaneous oscillations were also in-
duced by S3A8 treatment to begin Ca
 
2
 
  
 
oscillations with
Ca
 
2
 
  
 
transients of increasing frequency and subsequent Ca
 
2
 
 
 
accumulation (Video 3 and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041859/DC1).
Sera from p200-immunized rats had effects similar to
S3A8. With sera from two different p200-immunized ani-
Figure 2. Immunization of rats with p200 peptide leads to AV block 
in the offspring. Rats immunized with p200 developed an antibody re-
sponse against p200 (A) and full-length Ro52 (B), whereas rats immunized 
with control peptide did not. (C) No epitope spreading to adjacent Ro52 
peptides was observed in p200-immunized animals, although to some ex-
tent antibodies did bind to the highly overlapping p197 peptide. (D) The 
induced anti-p200 antibodies were mainly of IgG2a, IgG2b, and IgG2c 
subclasses in mothers as well as pups. (E) Immunized rats were mated and 
antibody titers and AV time were monitored in the pups by ECG performed 
on all pups within 12 h after birth. HR, heart rate. ECGs were sampled for 
5 s four times per minute and the PR interval was calculated from an 
averaged complex (F). Arrows denote start and end points for measurements 
on the averaged ECG. (G) ECG from a total of 52 pups from p200-immunized 
rats was analyzed and 10 (19%) had a first-degree AV block (filled symbols). 
The horizontal line marks the mean PR interval of the 26 pups from control 
immunized animals (mean   SD; 58.9   3.2). 
R
 
O
 
52 AUTOANTIBODIES INDUCE CONGENITAL HEART BLOCK | Salomonsson et al.
 
14
 
mals, an initial increased Ca
 
2
 
  
 
frequency oscillation activity
was noted (Fig. 4 D). Most cells in cultures treated with anti-
p200 sera had lost all Ca
 
2
 
  
 
oscillation activity after 60 min
and showed intracellular Ca
 
2
 
  
 
accumulation (Fig. 4, E and
F), though a few cells oscillating at low frequency still re-
mained. These cells were also active at 24 h of examination.
The effects were not observed with control sera from two
control peptide–immunized animals (not depicted).
These studies demonstrate that anti-Ro52 antibodies with
specificity for the p200 epitope confer the pathogenic effects
during development of congenital heart block and might be
used as a serologic correlate for the development of heart
block. However, our data suggest that not all anti-p200 anti-
bodies are pathogenic. We believe that anti-p200 antibodies
with the fine specificity profile of S3A8 constitute the patho-
genic antibodies, as these antibodies directly bind cardiomyo-
cytes, alter Ca
 
2
 
  
 
homeostasis, and eventually lead to cell death
by apoptosis. We suggest that these pathogenic effects are not
caused by interaction with Ro52, as this protein is intracellu-
lar, but that the antibodies are potentially binding a cross-
reactive self-antigen on the cell surface of cardiomyocytes.
Apoptosis has been shown to occur in congenital heart
Figure 3. An epitope within the predicted leucine zipper structure is 
recognized by similar antibodies from congenital heart block children, 
rat pups, and selected human anti-p200 monoclonals. (A) Ribbon 
structure representation of the predicted p200 secondary structure fold, 
including the leucine zipper motif. Leucines are represented in gray. 
(B) Schematic drawing of the region around the predicted leucine zipper 
and mutated peptides used in epitope mapping of anti-p200 antibodies. 
The amino acid sequence of p197 and p200 (leucines in gray and under-
lined) are shown, as well as indications of amino acid substitutions in the 
mutated peptides (pZIP in blue and in pOUT in red). The antigenic contri-
bution from the COOH-terminal amino acid was investigated by an ala-
nine scan of amino acids 233–239. S3A8 (C) and M4H1 (D) binding to the 
peptides was investigated. Sera from children with congenital heart block 
(E) and pups from p200-immunized animals with first-degree AV block (F) 
contained mainly S3A8 idiotype-like p200-specific antibodies. The level of 
p200 reactivity in each monoclonal or individual was set as 1 and the values 
for each monoclonal/individual normalized against their respective p200 
reactivity is shown. 
JEM VOL. 201, January 3, 2005
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block–affected fetal hearts (5), and it has been suggested that
Ro52-antibodies bind to the Ro52 protein exposed on the
surface of naturally occurring apoptotic cells of the develop-
ing heart. Our results, however, demonstrate that the Ro52
antibodies of p200 specificity in fact induce the apoptotic
process by causing Ca
 
2
 
  
 
overload, thereby potentially initiat-
ing the whole process of heart block development. In con-
clusion, multiple lines of investigation presented in our paper
including data from patients, an animal model, and in vitro
studies, all indicate that antibodies of S3A8-like p200 speci-
ficity initiate heart block development by dysregulating Ca
 
2
 
 
 
homeostasis. We suggest that this antibody specificity is the
essential and initiating factor in the development of congeni-
tal heart block and that it could be used clinically as a tool to
identify high risk pregnancies, thereby enabling early treat-
ment and prevention of congenital block.
Figure 4. S3A8 anti-p200 monoclonals and sera from p200-
immunized rats, but not M4H1, p200 monoclonals, or vehicle bind 
cardiomyocytes and induce dysregulation of Ca2  homeostasis. (A) Pri-
mary cardiomyocytes prepared from neonatal rat hearts were stained with 
S3A8, M4H1, or PBS. (B) Primary cardiomyocyte cultures loaded with fluo-4 
before the addition of monoclonal antibodies or serum. (C) Single cell 
tracing of [Ca2 ]i (calcium dye fluorescence intensity in arbitrary units) 
after the addition of respective antibody or vehicle. (D) The mean relative 
frequency of Ca2  transients. (E) Change in baseline intracellular Ca2  
levels over time.  F% was calculated by dividing baseline fluorescence 
between transients by the original (time 0) baseline level. (D and E) A rep-
resentation of results from 10 independent experiments for S3A8, 6 inde-
pendent experiments for M4H1, 5 independent experiments for PBS, and 
2 experiments with 2 different rat sera (1:10). Each rat serum is depicted 
individually (D and E). (F) Baseline fluorescence intensity after 20 min of 
substance application is depicted. A scale of 0–250 arbitrary units was 
used, where intensity of average pixel fluorescence signal is saturated 
when color turns blue ( 250 arbitrary units). 
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MATERIALS AND METHODS
 
Patients.
 
25 pregnant anti-Ro52
 
  
 
women were included consecutively
upon referral to the Pediatric Cardiology Unit at Karolinska Hospital for mon-
itoring during pregnancy (Table S1, available at http://www.jem.org/cgi/
content/full/jem.20041859/DC1). Blood was drawn from the mothers during
pregnancy at the time of fetal echocardiography. Blood from the children was
drawn 1–3 d after birth. The Human Ethics committee at the Karolinska Hos-
pital approved the study and informed consent was obtained from the mothers.
 
Recombinant proteins and synthetic peptides.
 
Recombinant Ro52,
Ro60, and La protein were expressed and purified as described previously
(9). Ro52 peptides p136-p200, pZIP, pOUT, and pA233-pA239 were pur-
chased from Thermo BioSciences.
 
ELISA for detection of antibodies to Ro52, Ro60, La, and Ro52
peptides.
 
ELISA for human sera was performed as described previously
(9). Sera were tested at a 1:1,000 dilution. Rat sera were analyzed at 1:2,500,
and bound antibodies were detected using rabbit anti–rat IgG, IgG1, IgG2a,
IgG2b, or IgG2c (Nordic).
 
Echocardiography recordings in humans.
 
All fetal echocardiography
recordings and measurements were performed by the same examiner (S.-E.
Sonesson) using a Sequoia ultrasound system with a 6C2 transducer (Acu-
son) as described previously (3). 284 women with normal pregnancies were
used to set reference threshold values (3, 14). First-degree AV block was de-
fined as at least two consecutive examinations with AV time intervals 
 
 
 
95%
confidence interval limits for normal fetuses. The method is described in
detail in the Supplemental Materials and Methods section, which is available
at http://www.jem.org/cgi/content/full/jem.20041859/DC1.
 
Immunization and ECG recordings in rats.
 
6-wk-old female DA rats
(B&K) were immunized with p200 or virally derived control JB4 peptide
(amino acid sequence GIWGCSGKLICTTAVPWNAS; reference 15). Rats
were mated 2–4 wk after the last booster. The Stockholm North Ethics
Committee approved the study.
On the day of delivery, three lead ECGs were recorded from conscious
pups using four silver microelectrodes attached to a body clip (16). The
ECG was digitalized and files were recorded for at least 3 min for each pup
and analyzed with Pharmlab (AstraZeneca). AV block I was defined as PR
intervals in control animals 
 
 
 
2 SD.
 
Expression of scFv antibodies.
 
Expression and purification of scFv anti-
body fragments were performed as described previously (12). The purified
antibodies were dialyzed against several changes of PBS and filtered for ste-
rility before use.
 
Preparation of primary cardiomyocyte cell cultures from rat
pups.
 
Cultures of cardiomyocytes were prepared using a kit (Worthington
Biochemical Corporation). Hearts from 1-d-old DA rats were dissected and
prepared according to the manufacturer’s instructions. The cardiomyocytes
were cultured in DMEM/F12 supplemented with 10% FCS, 1 
 
 
 
g/ml gen-
tamicin, 2.5 
 
 
 
g/ml insulin, 2.5 
 
 
 
g/ml transferrin, 2.5 ng/ml selenin, 30
 
 
 
g/ml BrdU, and 15 mM Hepes at 37
 
 
 
C with 5% CO
 
2
 
.
 
Immunohistochemical staining.
 
For cell surface staining, cardiomyo-
cytes were cultured for 4–5 d on glass slides coated with collagen type I (BD
Biosciences). After this, all steps until fixation were performed at 4
 
 
 
C. Slides
were incubated with S3A8 or M4H1 antibody, followed by anti-VSV
(1:2,500; Boehringer) and TRITC-conjugated goat anti–mouse antibodies
(Jackson ImmunoResearch Laboratories). Cells were fixed in 4% parafor-
maldehyde and stained with Hoechst 33258 (Farbwerke Hoechst) before
analysis in a confocal microscope (Eclipse TE300; Nikon).
Caspase-3 and TUNEL stainings were performed on cells fixed in 2%
formaldehyde with a polyclonal rabbit anti–caspase-3 antibody (0.3 
 
 
 
g/ml;
AF835; R&D Systems) and a cell death detection kit (POD; Roche).
 
Calcium level measurements.
 
Cardiomyocytes prepared as described
above were cultured on polylysine-covered glass slips (VWR) for 5 d. Cells
were loaded with the Ca
 
2
 
  
 
indicator fluo-4 acetoxymethylester (fluo-4
a.m.; Molecular Probes) by incubation for 50 min at 37
 
 
 
C, 5% CO
 
2
 
, in
conditioned medium containing 2 mM fluo-4 a.m. mixed with pluronic
acid (final concentration: 0.2%). This was followed by 20 min of deesterifi-
cation before measurements began. The coverslips were mounted in a
chamber with conditioned medium (37
 
 
 
C) and analyzed with an inverted
confocal microscope (TCS SP; Leica). 20 min of consecutive images col-
lected every 1.705 s (and in some cases every 0.7 s) were recorded for each
experiment. Cells were returned to the incubator and reexamined 60 min
and 24 h after drug application.
Images were processed with the ImageJ software (NIH) and imported
into Microcal Origin 7.5 (Originlab.com) for further analysis.
 
Statistical analysis.
 
The Mann-Whitney U test was used to compare au-
toantibody levels between pregnant women with and without fetal AV
block. A p-value of 
 
 
 
0.05 was considered significant.
 
Online supplemental material.
 
Video 1 illustrates echocardiographic
recordings from a fetal heart with signs of first degree AV block, and in
Video 2, the complete third-degree AV block after progression in the same
patient is shown. Fig. S1 contains explanatory anatomical labels for Video 1
and 2. Video 3 contains a film recorded in the confocal microscope of flou-
4–loaded cardiomyocytes before and after the addition of S3A8 antibody,
and in Fig. S2 a single cell tracing of [Ca
 
2
 
 
 
]
 
i 
 
from this experiment is shown.
Table S1 contains information on the patients. Videos 1–3, Figs. S1 and S2,
and Table S1 are available at http://www.jem.org/cgi/content/full/jem.
20041859/DC1.
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